<DOC>
	<DOCNO>NCT02808819</DOCNO>
	<brief_summary>The purpose study continue characterize safety profile benralizumab administration monitor pharmacodynamic activity drug asthma patient remain treatment least 16 week 40 week predecessor study D3250C00021 ( BORA ) .</brief_summary>
	<brief_title>A Safety Extension Study With Benralizumab Asthmatic Adults Inhaled Corticosteroid Plus Long-acting β2 Agonist</brief_title>
	<detailed_description>This open-label safety extension study design evaluate safety tolerability fix 30 mg dose benralizumab administer subcutaneously ( SC ) severe asthma patient inhaled corticosteroid long-acting β2 agonist ( ICS-LABA ) therapy without chronic oral corticosteroid ( OCS ) and/or asthma controller . All patient receive active drug dose regimen receive BORA . In order protect blind BORA , patient remain blinded treatment regimen allocation complete end treatment ( EOT ) assessments BORA sign informed consent participation study , treatment allocation unblinded investigator patient .</detailed_description>
	<criteria>Informed consent study participation must obtain prior study related procedure perform accord international guideline and/or applicable European Union guideline . Female male patient complete least 16 40 week Study D3250C00021 . Women childbearing potential ( WOCBP ) must agree use effective form birth control throughout study duration 16 week last dose Investigational Product ( IP ) For WOCBP : Have negative urine pregnancy test prior administration IP Visit 1 . All male patient sexually active must agree use double barrier method contraception ( condom spermicide ) first dose IP 16 week last dose . Any disorder include limited cardiovascular , gastrointestinal , hepatic , renal , neurological , musculoskeletal , infectious , endocrine , metabolic , hematological , psychiatric major physical impairment stable opinion Investigator could : Affect safety patient throughout study Influence finding study interpretation Impede patient 's ability complete entire duration study A helminth parasitic infection diagnose predecessor study either required hospitalization , treat , incompletely treat failed respond standard care therapy Any clinically significant change physical examination , vital sign , ECG , hematology , clinical chemistry , urinalysis predecessor study opinion investigator may put patient risk his/her participation study , may influence result study , interfere patient 's ability complete entire duration study Current malignancy malignancy develop predecessor study ( subject basal cell carcinoma , localize squamous cell carcinoma skin resect cure , situ carcinoma cervix treated/cured exclude ) . Receipt live attenuate vaccine within 30 day prior initiation treatment study , treatment period , 16 week ( 5 halflives ) last dose IP Receipt immunoglobulin blood product within 30 day prior Visit 1 Planned major surgical procedure conduct study Previous participation present study Concurrent enrolment another drugrelated interventional clinical trial AstraZeneca staff involve planning and/or conduct study Employees study center individual involve conduct study immediate family member individual Patients important protocol deviation predecessor study discretion Sponsor Patients ongoing serious adverse event ( SAEs ) prior study enrol extension study SAE resolve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchial Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Obstructive Lung Diseases</keyword>
</DOC>